The telemedicine service Doctis will buy out a controlling stake (51%) of the contract research company IPHARMA. The deal is expected to be closed by the end of 2021, its terms has not been disclosed.
The combined team will create a digital clinical research platform that will be part of the Doctis ecosystem. The service will provide an opportunity to organize communication between a patient and a doctor remotely. At the same time, the processing of the obtained data, their layout, comparison of research results will be carried out using artificial intelligence.